TSCAN THERAPEUTICS, INC.
Last · NASDAQ$0.2106-0.0064 (-2.95%)close · yahoo · 19h ago
Market cap$13.76M61.1M sh
P/E · TTM-0.2fwd -0.4 · eps -0.90 · loss
Beta1.14vs S&P 500
Div yield0.00%annual · TTM
52w range
$0.2014$2.57
Volume546.6Ksession
| Revenue | $10.3M |
|---|---|
| Operating income | $-135.8M |
| Net income | $-129.8M |
| Free cash flow | $-139.7M |
| Operating margin | -1315.4% |
| Net margin | -1256.8% |
| Return on equity | -105.4% |
| Period | 2025 |
Loading chart…
OpenFilings analyst
Our analyst
From latest 10-K · 2026-03-04
- Sbc Revenue High
- Operating Cf Burn
- Net Margin Sharply Negative
- Cash Conversion Weak
- Cash Runway Low
- Accumulated Deficit High
- Rd Intensity High
Red flags
- Sbc Revenue High — SBC/Revenue 113.4%
- Operating Cf Burn — Negative operating cash flow
- Net Margin Sharply Negative — Net margin -1256.8%
- Cash Conversion Weak — Cash conversion (CFO/Rev) -1310.6%
- Cash Runway Low — Cash runway ~1.1 years
- Accumulated Deficit High — Accumulated deficit / equity 410%
- Rd Intensity High — R&D/Revenue 1105.6%
Press & signals
- GlobeNewswire
TScan Therapeutics Announces Strategic Reorganization to Focus on in vivo Cell Therapy for Solid Tumors
- GlobeNewswire
TScan Therapeutics Reports Second Quarter 2026 Financial Results and Provides Corporate Update
Documents
FormReporting forFiledFlags